ReviewMetabolites2024
Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future Trends.
Review in Metabolites, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Harnessing metabolomics and proteomics in a clinical trial for pulmonary arterial hypertension: insights from post-hoc analysis of the REHAB-PH trial.EBioMedicine · 2026Trial
- Multi-Omics-Guided Design and Safety Engineering of Nucleic Acid Therapeutics: From Molecular Perturbation to Predictive Toxicology and Precision Translation.Chemical biology & drug design · 2026Review
- Antioxidant Activity of EthanolicMolecules (Basel, Switzerland) · 2026Article
- The data substrate of exposome intelligence: an interoperability profile for untargeted metabolomics.Frontiers in artificial intelligence · 2026Article
- AI redefine untargeted metabolomics: estimating chemical amounts for a Human Exposome Project.Frontiers in public health · 2026Review
- Microphysiological systems as a pillar of the Human Exposome Project.The Journal of biological chemistry · 2025Review
- Metabolomics as a tool for understanding and treating triple-negative breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Metabolomics profiling of hypervitaminosis A in South African preschoolers is characterised by modified serum lysophospholipids and oxylipins.The British journal of nutrition · 2025Article
- Zebrafish metabolomics: a comprehensive approach to understanding health and disease.Functional & integrative genomics · 2025Review
- Comprehensive metabolomics study identifies SN-38 organ specific toxicity in mice.Scientific reports · 2025Article
- Metabolomic insights of cultured meat compared to conventional meat.Scientific reports · 2025Article
- AI redefines mass spectrometry chemicals identification: retention time prediction in metabolomics and for a Human Exposome Project.Frontiers in public health · 2025Review
- A comprehensive review on computational metabolomics: Advancing multiscale analysis throughComputational and structural biotechnology journal · 2025Review
- Drug response in the era of precision medicine: A methodological review.Computational and structural biotechnology journal · 2025Review
- Overview of Bovine Mastitis: Application of Metabolomics in Screening Its Predictive and Diagnostic Biomarkers.Animals : an open access journal from MDPI · 2024Review
- NMR-based metabolomics for investigating urinary profiles of metal carpentry workers exposed to welding fumes and volatile organic compounds.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Metabolomics is emerging as a powerful systems biology approach for improving preclinical drug safety assessment. This review discusses current applications and future trends of metabolomics in toxicology and drug development. Metabolomics can elucidate adverse outcome pathways by detecting endogenous biochemical alterations underlying toxicity mechanisms. Furthermore, metabolomics enables better characterization of human environmental exposures and their influence on disease pathogenesis. Metabolomics approaches are being increasingly incorporated into toxicology studies and safety pharmacology evaluations to gain mechanistic insights and identify early biomarkers of toxicity. However, realizing the full potential of metabolomics in regulatory decision making requires a robust demonstration of reliability through quality assurance practices, reference materials, and interlaboratory studies. Overall, metabolomics shows great promise in strengthening the mechanistic understanding of toxicity, enhancing routine safety screening, and transforming exposure and risk assessment paradigms. Integration of metabolomics with computational, in vitro, and personalized medicine innovations will shape future applications in predictive toxicology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.